Cardiology Letters 2020, 29(4):243-247
Effect of growth hormone hypersecretion on the cardiovascular system
- V. interná klinika LF UK a UNB Bratislava, Slovenská republika
Growth hormone (GH) and insulin-like growth factor 1 (IGF-1) are molecules whose overproduction in patients with acromegaly leads to the development of cardiovascular comorbidities. The extent of the disease depends on the length of exposure of myocardial cells and endothelial cells to excessive concentrations of GH/IGF-1. However, the coexistence of other classical cardiovascular risk factors is also important. The most common cardiovascular comorbidities are arterial hypertension, acromegalic cardiomyopathy, valvular heart disease, arrhythmias and coronary artery disease. When a typical echocardiographic image of cardiomyopathy is present rare causes of cardiomyopathy should be considered, especially in young adults. Studies from recent years have shown a significant decrease in cardiovascular morbidity and mortality in patients with biochemically well-controlled disease. This paper summarizes the most commonly occurring cardiovascular comorbidities in patients with acromegaly, describing their pathophysiology and clinical management with an emphasis on early and adequate diagnosis.
Keywords: growth hormone; insulin-like growth factor 1; acromegaly; hypertension; atherosclerosis; cardiomyopathy
Published: April 1, 2020 Show citation
References
- El MehraouiO, Derakou N, Ezzerrouqi A, et al. Acromegaly complications at the time of diagnosis. Endocrine Abstracts. 2019;63:P680.
Go to original source... - Kužma M, Vaňuga P, Ságová I, et al. Non-invasive DXA-derived bone structure assessment of acromegaly patients: a crosssectional study. Eur J Endocrinol. 2019;180:201-211.
Go to original source... - Bondanelli M, Ambrosio MR, degli Uberti EC, et al. Pathogenesis and prevalence of hypertension in acromegaly. Pituitary. 2001;4:239-249.
Go to original source... - Ramos-Levi AM, Marazuela M. Bringing cardiovascular comorbidities in acromegaly to an update. How should we diagnose and manage them? Front Endocrinol. 2019;10: 1-11.
Go to original source... - Mercado M, Espinosa de los Monteros AL, Sosa E, et al. Clinicalbiochemical correlations in acromegaly at diagnosis and the real prevalence of biochemically discordant disease. Horm Res. 2004;62:293-299.
Go to original source... - Kamenicky P, Blanchard A, Frank M, et al. Body fluid expansion in acromegaly is related to enhanced epithelial sodium channel (ENaC) activity. J Clin Endocrinol Metab. 2011;96:2127-2135.
Go to original source... - Thomas JDJ, Dattani A, Zemrak F, et al. Renin-angiotensin system blockade improves cardiac indices in acromegaly patients. Exp Clin Endocrinol Diabetes. 2017;125:365-367.
Go to original source... - González B, Vargas G, de Los Monteros ALE, et al. Persistence of diabetes and hypertension after multimodal treatment of acromegaly. J Clin Endocrinol Metab. 2018;103:2369-2375.
Go to original source... - Guo X, Gao L, Zhao Z, et al. Characteristics of the upper respiratory tract in patients with acromegaly and correlations with obstructive sleep apnea/hypopnea syndrome. Sleep Med. 2018;48:27-34.
Go to original source... - Dlesk A, Kamensky G, Lazurova I, et al. The effect of growth hormone replacement therapy on the morphological and functional changes in the left ventricle in patients with adult-onset growth hormone deficiency. Wien Klin Wochenschr. 2014;126:480-484.
Go to original source... - Lazurova I, Pura M, Wagnerova H, et al. Effect of growth hormone replacement therapy on plasma brain natriuretic peptide concentration, cardiac morphology, and function in adults with growth hormone deficiency. Exp Clin Endocrinol Diabetes. 2010;118:172-176.
Go to original source... - Bogazzi F, Lombardi M, Strata E, et al. High prevalence of cardiac hypertrophy without detectable signs of fibrosis in patients with untreated active acromegaly: an in vivo study using magnetic resonance imaging. Clin Endocrinol. 2008;68:361-368.
Go to original source... - Godberg MD, Vadera N, Yandrapalli S, et al. Acromegalic cardiomyopathy: an overview of risk factors, clinical manifestations and therapeutic options. Cardiol Rev. 2018;26:307-311.
Go to original source... - Colao A, Ferone D, Marzullo P, et al. Systemic complications of acromegaly: epidemiology, pathogenesis and management. Endocr Rev. 2004;25:102-152.
Go to original source... - Colao A, Pivonello R, Galderisi M, et al. Impact of treating acromegaly first on surgery or somatostatin analogs on cardiomyopathy. J Clin Endocrinol Metab. 2008;93:2639-2646.
Go to original source... - Gadelha MR, Kasuki L, Lim DS, et al. Systemic complications of acromegaly and the impact of the current treatment landscape: an update. Endocrine Reviews. 2019;40:268-332.
Go to original source... - Colao A, Spinelli L, Marzullo P, et al. High prevalence of cardiac valve disease in acromegaly: An observational, analytical, casecontrol study. J Clin Endocrino lMetab. 2003;88:196-201.
Go to original source... - Pereira AM, van Thiel JR, Lindner F. Increased prevalence of regurgitant valvular heart disease in acromegaly. J Clin Endocrinol Metab. 2004;89:71-75.
Go to original source... - van der Klaauw JJ, Bax JW, Roelfsema GB, et al. Increased aortic root diameters in patients with acromegaly. Eur J Endocrinol. 2008;159:97-103.
Go to original source... - Colao A, Marek J, Goth MI, et al. No greater incidence or worsening of cardiac valve regurgitation with somatostatin analog treatment of acromegaly. J Clin Endocrinol Metab. 2008;93:2243-2248.
Go to original source... - Mosca S, Paollilo S, Colao A, et al. Cardiovascular involvment in patients affected by acromegaly: an appraisal. Int J Cardiol. 2013;167:1712-1718.
Go to original source... - Warszawski L, Kasuki L, Sa R, et al. Low frequency of cardiac arrhythmias and lack of structural heart disease in medicallynaive acromegaly patients: a prospective study at baseline and after 1 year of somatostatin analogs treatment. Pituitary. 2016;19:582-589.
Go to original source... - Klrls A, Erem C, Turan OE, et al. Left ventricular synchronicity is impaired in patients with active acromegaly. Endocrine. 2013;44:200-206.
Go to original source... - Unubol M, Eryilmaz U, Guney E, et al. QT dispersion in patients with acromegaly. Endocrine. 2013;43:419-423.
Go to original source... - Dos Santos Sila CM, Lima GA, Volschan IC, et al. Low risk of coronary artery disease in patients with acromegaly. Endocrine. 2015;50:749-755.
Go to original source... - Dekkers OM, Biermasz NR, Perreira AM, et al. Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab. 2008;93:61-67.
Go to original source... - Giustina A, Barkan A, Beckers A, et al. A consensus on the diagnosis and treatment of acromegaly comorbidities: an update. J Clin Endocrinol Metab. 2020;105:e937-e946.
Go to original source... - Bernabeu I, Aller J, Alvarez-Escola C, et al. Criteria for diagnosis and postoperative control of acromegaly, and screening and management of its comorbidities: Expert consensus. Endocrinologia, Diabetes y Nutricion (English ed.). 2018;65:297-305.
Go to original source...

